Experimental immune booster tested before breast cancer treatment
NCT ID NCT02950259
Summary
This early-stage study tested the safety of an experimental immune therapy called IRX-2 in people with early-stage breast cancer. Sixteen participants received IRX-2 injections near the tumor before their planned surgery or chemotherapy. Researchers wanted to see if the treatment was safe and if it changed the immune cells inside the tumor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
Conditions
Explore the condition pages connected to this study.